SCHEMBL785503

SCHEMBL785503

O=C1CC2CCCCC2N1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
MAP3K14 Q99558 1/20 0.34
SMYD3 Q9H7B4 1/20 0.34
OPRM1 P35372 2/20 0.33
OPRL1 P41146 2/20 0.33
MAPT P10636 1/20 0.33
OPRK1 P41145 1/20 0.33
PARP1 P09874 1/20 0.32
ITGB3 P05106 1/20 0.31
ITGB2 P05107 1/20 0.31
ITGB1 P05556 1/20 0.31
ITGAV P06756 1/20 0.31
ITGA2B P08514 1/20 0.31
ITGA5 P08648 1/20 0.31
ITGB5 P18084 1/20 0.31
ITGAL P20701 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10758827 1.00 ALDH1A1 (0.37) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL6685775 1.00 ALDH1A1 (0.37) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL5560867 1.00 ALDH1A1 (0.37) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL5560865 1.00 ALDH1A1 (0.37) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL8450841 1.00 ALDH1A1 (0.37) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL24311746 0.98 MAPT (0.36) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL17974614 0.98 MAPT (0.36) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL19671609 0.98 MAPT (0.36) ALDH1A1PKMLMNATSHRMAP3K14
SCHEMBL3738614 0.95
SCHEMBL22556208 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101597254-A A kind of Trolapril intermediates preparation SHANGHAI JINSHAN PHARMACEUTICA (CN) 2009-12-09 CN claimed
US-20070225505-A1 Method for the Preparation of (2S, 3AR, 7AS)-Octahydro-III-Indole-2-Carboxylic Acid as Key Intermediate in the Preparation of Trandolapril by Reacting a Cyclohexyl Aziridine with a Dialkyl Malonate TEXCONTOR ETABLISSEMENT (LI) 2007-09-27 US claimed
EP-1687271-A1 A METHOD FOR THE PREPARATION OF (2S, 3AR, 7AS)-OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID AS KEY INTERMEDIATE IN THE PREPARATION OF TRANDOLAPRIL BY REACTING A CYCLOHEXYL AZIRIDINE WITH A DIALKYL MALONATE Texcontor Etablissement (LI) 2006-08-09 EP claimed
WO-2005054194-A1 A METHOD FOR THE PREPARATION OF (2S, 3AR, 7AS)-OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID AS KEY INTERMEDIATE IN THE PREPARATION OF TRANDOLAPRIL BY REACTING A CYCLOHEXYL AZIRIDINE WITH A DIALKYL MALONATE TEXCONTOR ETABLISSEMENT (LI) 2005-06-16 WO claimed
US-20250376464-A1 Compounds for treatment a coronavirus infection TRAWSFYNYDD THERAPEUTICS INC (US) 2025-12-11 US disclosed
CN-114539267-B Evodiamine derivative and application thereof 中国人民解放军海军军医大学 2023-04-28 CN disclosed
US-10919863-B2 Compositions for the treatment of pulmonary fibrosis VECTUS BIOSYSTEMS LIMITED (AU) 2021-02-16 US disclosed
US-20190270712-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS VECTUS BIOSYSTEMS LIMITED (AU) 2019-09-05 US disclosed
US-10280189-B2 Method for the synthesis of aminoalkylenephosphonic acid MONSANTO TECHNOLOGY LLC (US) 2019-05-07 US disclosed
US-9738608-B2 Synthesis of lactam based ionic liquid UOP LLC (US) 2017-08-22 US disclosed
WO-2017133658-A1 4, 7-DIAZAINDOLE AND 4, 7-DIAZAINDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 WO disclosed
US-9630935-B2 Compositions for the treatment of hypertension and/or fibrosis VECTUS BIOSYSTEMS LIMITED (AU) 2017-04-25 US disclosed
EP-0668268-A2 Bicyclolactam derivatives for improving cerebral functions TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1995-08-23 EP disclosed
CN-1103534-A Compound with antipsychotic effect MEIJI SEIKA CO (JP) 1995-06-07 CN disclosed
EP-0635506-A1 COMPOUND WITH ANTIPSYCHOTIC EFFECT MEIJI SEIKA KABUSHIKI KAISHA (JP) 1995-01-25 EP disclosed
US-5214039-A Cognition activators TAIHO PHARMACEUTICAL CO., LIMITED (JP) 1993-05-25 US disclosed
US-5185344-A Improve cerebral function, activate cerebral metabolism, protect against anoxic brain damage TAIHO PHARMACEUTICAL COMPANY, LTD. (JP) 1993-02-09 US disclosed
EP-0466933-A1 BICYCLOLACTAM DERIVATIVE TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1992-01-22 EP disclosed
EP-0212588-B1 Saturated cycloalkyl [b] pyrrole-1(2H)-acetic acid amides and derivatives thereof WARNER-LAMBERT COMPANY (US) 1989-12-06 EP disclosed
EP-0212588-A1 Saturated cycloalkyl [b] pyrrole-1(2H)-acetic acid amides and derivatives thereof WARNER-LAMBERT COMPANY (US) 1987-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376464-A1 Compounds for treatment a coronavirus infection ACE2, ACE, TMPRSS2 ALDH1A1 1357/4885PKM 2736/4885LMNA 3894/4885
US-10919863-B2 Compositions for the treatment of pulmonary fibrosis ELANE, MMP1, CCL11 ALDH1A1 1395/4885PKM 2288/4885LMNA 1088/4885
US-20070225505-A1 Method for the Preparation of (2S, 3AR, 7AS)-Octahydro-III-Indole-2-Carboxylic Acid as Key Intermediate in the Preparation of Trandolapril by Reacting a Cyclohexyl Aziridine with a Dialkyl Malonate IDO1, TPH1, AGTR1 ALDH1A1 149/4885PKM 863/4885LMNA 2086/4885
US-20190270712-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS ELANE, MMP1, CCL11 ALDH1A1 1395/4885PKM 2288/4885LMNA 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.